Promoting rational therapy within the discipline of cardiology, the American Journal of Cardiovascular Drugs covers all aspects of the treatment of cardiovascular disorders, particularly the place in therapy of newer and established agents.

Via a program of reviews and original clinical research articles, the journal addresses major issues relating to treatment of these disorders, including the pharmacology, efficacy and adverse effects of the major classes of drugs; information on newly developed drugs and drug classes; the therapeutic implications of latest research into the aetiology of cardiovascular disorders; and the practical management of specific clinical situations.

As a hybrid journal, the American Journal of Cardiovascular Drugs does not charge authors to publish using the traditional subscription-based publishing route, but does offer the option to publish accepted articles open access if authors so wish or if their funders require. This is achieved via the Springer Open Choice™ initiative. More information about this optional route to open access and the associated article processing charge can be found by clicking on the ‘How to publish with us, including Open Access’ link below.

The American Journal of Cardiovascular Drugs offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by a Key Points summary, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. Peer review is conducted using Editorial Manager®, supported by a database of international experts. This database is shared with other Adis journals.

Journal information

Editor
  • Amitabh Prakash
Publishing model
Hybrid. How to publish with us, including Open Access

Journal metrics

3.283 (2021)
Impact factor
3.102 (2021)
Five year impact factor
16 days
Submission to first decision (Median)
134,880 (2021)
Downloads

Latest articles

This journal has 78 open access articles

Journal updates

  • Digital Features

    The American Journal of Cardiovascular Drugs is able to host a range of digital features, with a number of options available to authors.

    Digital features
View all updates

Societies, partners and affiliations

  • International Academy of Cardiovascular Sciences
    International Academy of Cardiovascular Sciences

About this journal

Electronic ISSN
1179-187X
Print ISSN
1175-3277
Abstracted and indexed in
  1. BFI List
  2. Baidu
  3. CLOCKSS
  4. CNKI
  5. CNPIEC
  6. Chemical Abstracts Service (CAS)
  7. Current Contents/Clinical Medicine
  8. Dimensions
  9. EBSCO Academic Search
  10. EBSCO CINAHL
  11. EBSCO Discovery Service
  12. EBSCO STM Source
  13. EMBASE
  14. Google Scholar
  15. Japanese Science and Technology Agency (JST)
  16. Journal Citation Reports/Science Edition
  17. Medline
  18. Naver
  19. OCLC WorldCat Discovery Service
  20. Pathway Studio
  21. Portico
  22. ProQuest-ExLibris Primo
  23. ProQuest-ExLibris Summon
  24. Reaxys
  25. SCImago
  26. SCOPUS
  27. Science Citation Index
  28. Science Citation Index Expanded (SCIE)
  29. Semantic Scholar
  30. TD Net Discovery Service
  31. UGC-CARE List (India)
  32. Wanfang
Copyright information

Rights and permissions

Springer policies

© Springer Nature Switzerland AG